Pharma & API
Key starting materials are frequently sourced from one site. Regulatory requalification, not manufacturing, is what keeps a second source from being an alternative.
Regulatory approval makes an ingredient shortage last after supply returns
This tier narrows because a replacement ingredient source cannot simply be purchased when the approved source fails. Drug makers must show that the new material and its manufacturing process meet the product’s existing quality standard before it can enter an approved medicine.
A stoppage therefore reaches patients through paperwork as well as chemistry. Manufacturers can hold inventory or find another producer, but neither restores supply until the replacement has cleared the required requalification; the delay falls on hospitals, pharmacies and the patients waiting for treatment.
Is regulatory requalification becoming the pacing step for this chain, rather than a symptom reported downstream?
- Observe
- Start at the named step: Key starting materials. Compare a source record for that step with the downstream delivery or recognition it is meant to constrain.
- Boundary
- This is a 5 tiers reference chain with a recorded substitution window of 18–24 m. It does not establish issuer exposure until a named record supports it.
- Breaks the read
- A verified record showing that an alternative clears inside 18–24 m, or that downstream delivery no longer moves with regulatory requalification, would weaken this chain read.
No matching illustrated investigation is currently packaged for this record. The method remains open; a reporting card appears only when a durable article exists.
This record does not name issuer-level exposure. Use the source registry before promoting a chain constraint into a company claim.
No family-specific series are asserted for this reference record.
Browse the source registry →No dated revision has been published for this chain record.